Blackrock Neurotech designs and manufactures implantable brain-computer interfaces, including the FDA-cleared NeuroPort Array, a 96-channel intracortical microelectrode that records and stimulates individual neurons. The platform translates neural activity into control signals so people with paralysis or motor disorders can move robotic limbs, type, navigate wheelchairs, and operate consumer software using only their thoughts.

Founded out of the University of Utah and built on the original Utah Array technology, the company has equipped most clinical brain-computer interface human studies to date. It pairs hardware, neural recording electronics, and decoder software for both research labs and a regulated medical-device pipeline targeting patients with spinal cord injury, ALS, stroke, and limb loss.